Results 151 to 160 of about 1,632,256 (263)

Immunohistochemical evaluation of T cell receptor and T cell receptor beta constant 1 expression distinguishes benign and neoplastic immature T-cell populations and reveals discrete TRBC1/TCR phenotypes. [PDF]

J Hematop
Chaudhary S, Courville EL, Craig J, Smith V, Moore M.   +4 more
europepmc   +1 more source

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment [PDF]

, 2015
Benjamin Kansy, Yan Lin, Fei Ding, Sandra P. Gibson, Hyun-Bae Jie, Robert L. Ferris   +5 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Spatial Proximity of LAG-3 and T Cell Receptor: A New Paradigm for T Cell Suppression. [PDF]

MedComm (2020)
Miao X, Feng X, Zhou F.
europepmc   +1 more source

Clonal rearrangements of T-cell receptor and immunoglobul in genes as sensitive marker for bone marrow involvement in non-Hodgkin's lymphoma [PDF]

, 1986
Martin Krönke, G. Krieger, Michael Kneba, Georg Nagel, Klaus Pfizenmaier   +4 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

The resting and ligand-bound states of the membrane-embedded human T-cell receptor-CD3 complex. [PDF]

Nat Commun
Notti RQ, Yi F, Heissel S, Bush MW, Molvi Z, Das P, Molina H, Klebanoff CA, Walz T.   +8 more
europepmc   +1 more source

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8⁺T cell responses in nonhuman primates

, 2005
Ulrike Wille-Reece, Barbara J. Flynn, Karin Loré, Richard A. Koup, Ross M. Kedl, Joseph J. Mattapallil, Walter R. Weiss, Mario Roederer, Robert A. Seder   +8 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

ALIGaToR: a tool for the automated annotation of immunoglobulin and T cell receptor genomic loci. [PDF]

Oxf Open Immunol
Schramm CA, Olubo S, Douek DC.
europepmc   +1 more source